We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+43%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$926M
AUM Growth
+$212M
Cap. Flow
-$7.45M
Cap. Flow %
-0.8%
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
24
Reduced
46
Closed
5

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$17.6M
2
BAX icon
Baxter International
BAX
+$8.28M
3
XLRN
Acceleron Pharma
XLRN
+$8.19M
4
UNH icon
UnitedHealth
UNH
+$7.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.7M
2
ESPR
Esperion Therapeutics
ESPR
+$7.02M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$6.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$5.93M
5
MGNX icon
MacroGenics
MGNX
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
2 Communication Services 1.03%
3 Energy 0.07%
4 Technology 0.06%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWAV
76
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$2.84M 0.31%
+60,000
New +$2.47M
ABEO icon
77
Abeona Therapeutics
ABEO
$425M
$2.7M 0.29%
37,000
-1,000
-3% -$69.1K
CLLS
78
Cellectis
CLLS
$278M
$2.57M 0.28%
144,604
– –
QURE icon
79
uniQure
QURE
$3.2B
$1.82M 0.2%
40,466
-25,332
-38% -$1.5M
VRAY
80
DELISTED
ViewRay, Inc.
VRAY
$1.74M 0.19%
775,000
-75,000
-9% -$160K
PVLA
81
Palvella Therapeutics
PVLA
$2.19B
$930K 0.1%
3,750
– –
CVX icon
82
Chevron
CVX
$382B
$265K 0.03%
2,974
– –
XOM icon
83
ExxonMobil
XOM
$662B
$241K 0.03%
5,388
– –
QCOM icon
84
Qualcomm
QCOM
$170B
$217K 0.02%
+2,381
New +$191K
IBM icon
85
IBM
IBM
$223B
$192K 0.02%
1,660
-657
-28% -$76.3K
JHG
86
DELISTED
Janus Henderson
JHG
$183K 0.02%
8,645
-2,000
-19% -$38.6K
F icon
87
Ford
F
$55.8B
$177K 0.02%
29,164
– –
JPM icon
88
JPMorgan Chase
JPM
$956B
$162K 0.02%
+1,723
New +$163K
DIS icon
89
Walt Disney
DIS
$178B
$149K 0.02%
+1,338
New +$148K
PFE icon
90
Pfizer
PFE
$154B
$147K 0.02%
+4,751
New +$161K
BUD icon
91
AB InBev
BUD
$164B
$138K 0.01%
+2,806
New +$131K
GEN icon
92
Gen Digital
GEN
$17.5B
$137K 0.01%
+6,926
New +$141K
WFC icon
93
Wells Fargo
WFC
$265B
$135K 0.01%
+5,272
New +$144K
HAL icon
94
Halliburton
HAL
$28B
$108K 0.01%
+8,299
New +$89.5K
SAGE
95
DELISTED
Sage Therapeutics
SAGE
– –
-50,000
Closed -$1.44M
VKTX icon
96
Viking Therapeutics
VKTX
$4.02B
– –
-200,000
Closed -$936K
ONC
97
BeOne Medicines Ltd
ONC
$40.6B
– –
-20,000
Closed -$2.46M
ICPT
98
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-40,000
Closed -$2.52M
STML
99
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-650,000
Closed -$3.15M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rhenman & Partners Asset Management held 99 positions worth $926M, up 30% from $714M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q2 2020 filing shows 14 new, 24 increased, 46 reduced and 5 closed positions. Its largest new stake was Gilead Sciences: 230,000 shares worth $17.7M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Communication Services and Energy.

  • Rhenman & Partners Asset Management's largest Q2 2020 buy was Gilead Sciences: 230,000 shares worth $17.7M.
  • Rhenman & Partners Asset Management added most to Acceleron Pharma in Q2 2020, an estimated $8.19M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $10.7M.
  • Rhenman & Partners Asset Management fully exited Stemline Therapeutics, Inc. in Q2 2020, selling an estimated $3.15M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $926M portfolio in Q2 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $926M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.